Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

283 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
Kanjanapan Y, Day D, Butler MO, Wang L, Joshua AM, Hogg D, Leighl NB, Razak ARA, Hansen AR, Boujos S, Chappell M, Chow K, Sherwin B, Stayner LA, Soultani L, Zambrana A, Siu LL, Bedard PL, Spreafico A. Kanjanapan Y, et al. Among authors: hansen ar. Eur J Cancer. 2019 Jan;107:1-7. doi: 10.1016/j.ejca.2018.10.017. Epub 2018 Dec 7. Eur J Cancer. 2019. PMID: 30529898
Tumour heterogeneity in the clinic.
Bedard PL, Hansen AR, Ratain MJ, Siu LL. Bedard PL, et al. Among authors: hansen ar. Nature. 2013 Sep 19;501(7467):355-64. doi: 10.1038/nature12627. Nature. 2013. PMID: 24048068 Free PMC article.
Phase 1 trial design: is 3 + 3 the best?
Hansen AR, Graham DM, Pond GR, Siu LL. Hansen AR, et al. Cancer Control. 2014 Jul;21(3):200-8. doi: 10.1177/107327481402100304. Cancer Control. 2014. PMID: 24955703 Free article. Review.
Early phase clinical trials to identify optimal dosing and safety.
Cook N, Hansen AR, Siu LL, Abdul Razak AR. Cook N, et al. Among authors: hansen ar. Mol Oncol. 2015 May;9(5):997-1007. doi: 10.1016/j.molonc.2014.07.025. Epub 2014 Aug 14. Mol Oncol. 2015. PMID: 25160636 Free PMC article. Review.
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
Lassen UN, Meulendijks D, Siu LL, Karanikas V, Mau-Sorensen M, Schellens JH, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, Bottino D, Zhong H, Roessler M, Vega-Harring SM, Jarutat T, Geho D, Wang K, DeMario M, Goss GD. Lassen UN, et al. Among authors: hansen ar. Clin Cancer Res. 2015 Jan 15;21(2):258-66. doi: 10.1158/1078-0432.CCR-14-1334. Epub 2014 Nov 11. Clin Cancer Res. 2015. PMID: 25388164 Clinical Trial.
283 results